Skip to main content
Erschienen in: Surgery Today 2/2021

13.06.2020 | Short Communication

Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma?

verfasst von: Masatsugu Hamaji, Sho Koyasu, Mitsugu Omasa, Akiyoshi Nakakura, Satoshi Morita, Tatsuo Nakagawa, So Miyahara, Ryo Miyata, Yuhei Yokoyama, Kenzo Kawakami, Michiharu Suga, Mamoru Takahashi, Yasuji Terada, Yusuke Muranishi, Ryo Miyahara, Ryota Sumitomo, Cheng-Long Huang, Akihiro Aoyama, Yutaka Takahashi, Hiroshi Date

Erschienen in: Surgery Today | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to investigate the association between the volume-dependent parameters in 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG PET/CT) and a recurrence of thymic carcinoma. A retrospective chart review was performed based on our multi-institutional database to identify patients undergoing PET prior to resection of thymic carcinoma or neuroendocrine carcinoma between 1991 and 2018. The PET parameters (metabolic tumor volume and total lesion glycolysis) were evaluated retrospectively. The relevant factors were extracted and a survival analysis was performed using the Kaplan–Meier method. Sixteen patients were thus deemed to be eligible for analysis. The median follow-up period following resection was 2.65 years (range: 0.96–0.68 years). The recurrence-free survival was significantly longer in patients with a metabolic tumor volume <  = 22.755 cm3 and with total lesion glycolysis <  = 105.4006 g/mL (p = 0.001 and 0.001, respectively, by a log-rank test). The metabolic tumor volume and total lesion glycolysis may, therefore, be predictive of the postoperative recurrence of thymic carcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat NCCN clinical practice guidelines in Oncology. Thymomas and thymic carcinomas, Available at, NCCN, https://www.nccn.org/professionals/physician_gls/pdf/thymic_blocks.pdf. NCCN clinical practice guidelines in Oncology. Thymomas and thymic carcinomas, Available at, NCCN, https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​thymic_​blocks.​pdf.​
2.
Zurück zum Zitat Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. ESMO Guidelines Committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):40–55.CrossRef Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. ESMO Guidelines Committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):40–55.CrossRef
3.
Zurück zum Zitat Benveniste MF, Moran CA, Mawlawi O, Fox PS, Swisher SG, Munden RF, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. 2013;8:502–10.CrossRef Benveniste MF, Moran CA, Mawlawi O, Fox PS, Swisher SG, Munden RF, et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol. 2013;8:502–10.CrossRef
4.
Zurück zum Zitat Park SY, Cho A, Bae MK, Lee CY, Kim DJ, Chung KY. Value of 18F-FDG PET/CT for predicting the world health organization malignant grade of thymic epithelial tumors: focused in volume-dependent parameters. Clin Nucl Med. 2016;41:15–20.CrossRef Park SY, Cho A, Bae MK, Lee CY, Kim DJ, Chung KY. Value of 18F-FDG PET/CT for predicting the world health organization malignant grade of thymic epithelial tumors: focused in volume-dependent parameters. Clin Nucl Med. 2016;41:15–20.CrossRef
5.
Zurück zum Zitat Fukumoto K, Taniguchi T, Ishikawa Y, Kato K, et al. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours. Eur J Cardiothorac Surg. 2012;42:152–6.CrossRef Fukumoto K, Taniguchi T, Ishikawa Y, Kato K, et al. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours. Eur J Cardiothorac Surg. 2012;42:152–6.CrossRef
6.
Zurück zum Zitat Treglia G, Sadeghi R, Giovanella L, Cafarotti S, Filosso P. Lococo F Is 18F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? Lung Cancer. 2014;86:5–13.CrossRef Treglia G, Sadeghi R, Giovanella L, Cafarotti S, Filosso P. Lococo F Is 18F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? Lung Cancer. 2014;86:5–13.CrossRef
7.
Zurück zum Zitat Shimizu H, Okada M, Tangoku A, Doki Y, Endo S, et al. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2017;68:414–49.CrossRef Shimizu H, Okada M, Tangoku A, Doki Y, Endo S, et al. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2017;68:414–49.CrossRef
8.
Zurück zum Zitat Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9:e105682.CrossRef Hirata K, Kobayashi K, Wong KP, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS ONE. 2014;9:e105682.CrossRef
9.
Zurück zum Zitat Koyasu S, Nakamoto Y, Kikuchi M, Suzuki K, Hayashida K, Itoh K, et al. Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma. AJR Am J Roentgenol. 2014;202:851–8.CrossRef Koyasu S, Nakamoto Y, Kikuchi M, Suzuki K, Hayashida K, Itoh K, et al. Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma. AJR Am J Roentgenol. 2014;202:851–8.CrossRef
10.
Zurück zum Zitat Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–44.CrossRef Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–44.CrossRef
11.
Zurück zum Zitat Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg. 2015;149:95–100.CrossRef Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg. 2015;149:95–100.CrossRef
12.
Zurück zum Zitat Okumura M, Yoshino I, Yano M, Watanabe SI, Tsuboi M, Yoshida K, et al. Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma. Eur J Cardiothorac Surg. 2019;56:174–81.CrossRef Okumura M, Yoshino I, Yano M, Watanabe SI, Tsuboi M, Yoshida K, et al. Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma. Eur J Cardiothorac Surg. 2019;56:174–81.CrossRef
13.
Zurück zum Zitat Kikuchi M, Koyasu S, Shinohara S, Usami Y, Imai Y, Hino M, et al. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status. Head Neck. 2015;37:1524–31.CrossRef Kikuchi M, Koyasu S, Shinohara S, Usami Y, Imai Y, Hino M, et al. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status. Head Neck. 2015;37:1524–31.CrossRef
14.
Zurück zum Zitat Mathew B, Purandare NC, Puranik A, Shah S, Agrawal A, Pramesh CS, et al. Prognostic value of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography in surgically resected non-small cell lung cancer patients. World J Nucl Med. 2020;19:8–14.CrossRef Mathew B, Purandare NC, Puranik A, Shah S, Agrawal A, Pramesh CS, et al. Prognostic value of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography in surgically resected non-small cell lung cancer patients. World J Nucl Med. 2020;19:8–14.CrossRef
15.
Zurück zum Zitat Hamaji M, Shah RM, Ali SO, Bettenhausen A, Lee HS, Burt BM. A Meta-Analysis of postoperative radiotherapy for thymic carcinoma. Ann Thorac Surg. 2017;103:1668–755.CrossRef Hamaji M, Shah RM, Ali SO, Bettenhausen A, Lee HS, Burt BM. A Meta-Analysis of postoperative radiotherapy for thymic carcinoma. Ann Thorac Surg. 2017;103:1668–755.CrossRef
16.
Zurück zum Zitat Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database. J Thorac Oncol. 2014;9:541–8.CrossRef Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database. J Thorac Oncol. 2014;9:541–8.CrossRef
17.
Zurück zum Zitat Hishida T, Nomura S, Yano M, Asamura H, Yamashita M, Ohde Y, et al. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur J Cardiothorac Surg. 2016;49:835–41.CrossRef Hishida T, Nomura S, Yano M, Asamura H, Yamashita M, Ohde Y, et al. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur J Cardiothorac Surg. 2016;49:835–41.CrossRef
18.
Zurück zum Zitat Song Z, Zhang Y. Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre. Eur J Surg Oncol. 2014;40:1523–7.CrossRef Song Z, Zhang Y. Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre. Eur J Surg Oncol. 2014;40:1523–7.CrossRef
Metadaten
Titel
Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma?
verfasst von
Masatsugu Hamaji
Sho Koyasu
Mitsugu Omasa
Akiyoshi Nakakura
Satoshi Morita
Tatsuo Nakagawa
So Miyahara
Ryo Miyata
Yuhei Yokoyama
Kenzo Kawakami
Michiharu Suga
Mamoru Takahashi
Yasuji Terada
Yusuke Muranishi
Ryo Miyahara
Ryota Sumitomo
Cheng-Long Huang
Akihiro Aoyama
Yutaka Takahashi
Hiroshi Date
Publikationsdatum
13.06.2020
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 2/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02045-z

Weitere Artikel der Ausgabe 2/2021

Surgery Today 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.